newsfilter
← Latest News
GlobeNewswire·

Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025

ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid, Nav 1.7 inhibitor